Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,463 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03820986 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | completed | Phase 3 | 674 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Feb 9, 2026 | clinicaltrials |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | active not recruiting | Phase 3 | 331 | Gilead SciencesINDUSTRY | 3 | Feb 9, 2026 |
| clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen(CHONQUER) | recruiting | Phase 3 | 136 | Servier Bio-Innovation LLCINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT04776148 | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | completed | Phase 3 | 563 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Feb 5, 2026 | clinicaltrials |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | completed | Phase 3 | 804 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 4, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT05061823 | Bintrafusp Alfa Program Rollover Study | completed | Phase 3 | 22 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer(STAR-121) | active not recruiting | Phase 3 | 1,021 | Gilead SciencesINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT06704945 | No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy(Neo-NAUTILUS) | recruiting | Phase 3 | 464 | Seoul National University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT03456063 | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Jan 22, 2026 | clinicaltrials |
| NCT04165317 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer(CREST) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 14 | Jan 22, 2026 | clinicaltrials |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | completed | Phase 3 | 571 | NovoCure Ltd.INDUSTRY | 20 | Jan 21, 2026 | clinicaltrials |
| NCT03972488 | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET(NETTER-2) | active not recruiting | Phase 3 | 226 | Advanced Accelerator ApplicationsINDUSTRY | 9 | Jan 21, 2026 | clinicaltrials |
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY) | active not recruiting | Phase 3 | 545 | Eli Lilly and CompanyINDUSTRY | 14 | Jan 16, 2026 | clinicaltrials |
| NCT05169567 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer(postMONARCH) | active not recruiting | Phase 3 | 368 | Eli Lilly and CompanyINDUSTRY | 17 | Jan 16, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY | 36 | Jan 13, 2026 | clinicaltrials |
| NCT01856478 | LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 340 | Boehringer IngelheimINDUSTRY | 8 | Jan 12, 2026 | clinicaltrials |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | active not recruiting | Phase 3 | 633 | AmgenINDUSTRY | 31 | Jan 12, 2026 | clinicaltrials |
| NCT03474107 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | completed | Phase 3 | 608 | Astellas Pharma Global Development, Inc.INDUSTRY | 19 | Jan 9, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer(DeLLphi-304) | active not recruiting | Phase 3 | 509 | AmgenINDUSTRY | 31 | Jan 5, 2026 | clinicaltrials |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | completed | Phase 3 | 236 | Radiation Therapy Oncology GroupNETWORK | 4 | Dec 31, 2025 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT04592913 | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | active not recruiting | Phase 3 | 957 | AstraZenecaINDUSTRY | 20 | Dec 24, 2025 | clinicaltrials |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | active not recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Dec 24, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT04447118 | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy(PYRAMID-1) | completed | Phase 3 | 151 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 19, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) | active not recruiting | Phase 3 | 563 | AmgenINDUSTRY | 29 | Dec 17, 2025 | clinicaltrials |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 337 | SanofiINDUSTRY | 24 | Dec 12, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
| NCT03924869 | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | terminated | Phase 3 | 448 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Dec 11, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials